{"id":745228,"date":"2015-04-08T06:30:00","date_gmt":"2015-04-08T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/"},"modified":"2025-11-07T01:25:17","modified_gmt":"2025-11-07T06:25:17","slug":"advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/","title":{"rendered":"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer"},"content":{"rendered":"<p class=\"bwalignc\"><i>KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer<\/i><\/p>\n<p><a href=\"http:\/\/www.advaxis.com\/\"><b>Advaxis, Inc.<\/b><\/a><b> <\/b>(NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1\/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational <i>Lm<\/i>-LLO immunotherapy, and KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis\u2019s lead <i>Lm<\/i>-LLO immunotherapy candidate for prostate cancer.&nbsp; It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer.&nbsp;<\/p>\n<p>ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis <i>Lm<\/i>-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.&nbsp;<\/p>\n<p>\u201cA synergistic anti-tumor immune response has been observed in preclinical studies evaluating the combination of a PD-1 antibody with an <i>Lm<\/i>-LLO immunotherapy, and we look forward to the possibility of seeing these results in patients. This immunotherapy combination could be a promising alternative treatment option to current standards of care,\u201d said Naomi B. Hass, M.D., Associated Professor of Medicine and Director of the Prostate and Kidney Cancer Program at the University of Pennsylvania Abramson Cancer Center and principal investigator for KEYNOTE-046.&nbsp;<\/p>\n<p>\u201cThe KEYNOTE-046 combination immunotherapy study is a significant clinical development milestone for our <i>Lm<\/i>-LLO immunotherapy platform, as well as the advancement of ADXS-PSA as a potential treatment for advanced prostate cancer,\u201d said Daniel J. O\u2019Connor, President and Chief Executive Officer of Advaxis. \u201cFurther, for Advaxis, the initiation of this clinical program continues what has been a rapid progression of our pipeline, which we hope will further demonstrate the value of our immunotherapy technology alone and in combination with checkpoint inhibitors.\u201d&nbsp;<\/p>\n<p>\u201cThe initiation of new combination studies with KEYTRUDA is an example of our focus on advancing breakthrough science in the field of immuno-oncology,\u201d said Eric Rubin, M.D., vice president and therapeutic area head, early-stage oncology development, Merck Research Laboratories. \u201cWe are pleased this study with Advaxis has begun and we look forward to gaining a better understanding of the potential of KEYTRUDA and ADXS-PSA, two immunotherapies with varying mechanisms, in advanced prostate cancer.\u201d<\/p>\n<p>KEYNOTE-046 is a multicenter, dose determining, open-label Phase 1\/2 study designed to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with KEYTRUDA in approximately 51 mCRPC patients. Part A of the study will be a dose escalating study designed to establish the maximum tolerated dose of ADXS-PSA as a monotherapy. Part B will consist of a dose escalating trial of ADXS-PSA in combination with KEYTRUDA, followed by an expansion cohort phase. The primary objective is to evaluate safety and tolerability of the two immunotherapies, with the secondary objective to evaluate anti-tumor activity and progression-free survival (PFS). Further information about KEYNOTE-046 can be found on <a href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/a>, using Identifier NCT02325557.&nbsp;<\/p>\n<p><b>About Prostate Cancer<\/b><\/p>\n<p>Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in six will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that approximately 233,000 new cases of prostate cancer will be diagnosed and about 30,000 men are expected to die of the disease this year.<b>&nbsp;<\/b><\/p>\n<p><b>About ADXS-PSA<\/b><b>&nbsp;<\/b><\/p>\n<p>ADXS-PSA is an <i>Lm<\/i>-LLO immunotherapy that is designed to target the prostate-specific antigen (PSA), a protein produced exclusively by prostate cells that is associated with prostate cancer. ADXS-PSA secretes the PSA antigen, fused to the powerful immunostimulant tLLO, directly inside the antigen presenting cells that are capable of driving a cellular immune response to PSA expressing cells. This approach is also designed to inhibit the Treg and myeloid-derived suppressor cells (MDSCs) that contribute to immunologic tolerance of prostate cancer. In preclinical analysis, ADXS-PSA inhibits the immunosuppression caused by Treg and MDSC cells localized inside tumors that may promote immunologic tolerance of prostate cancer.&nbsp;<\/p>\n<p><b>About KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) <\/b><\/p>\n<p>KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.&nbsp;<\/p>\n<p>KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.&nbsp;<\/p>\n<p>Merck is advancing a broad and fast-growing clinical development program for KEYTRUDA with more than 70 clinical trials \u2013 across more than 30 tumor types and over 8,000 patients \u2013 both as a monotherapy and in combination with other therapies.<\/p>\n<p><b>Selected Important Safety Information for KEYTRUDA<\/b><\/p>\n<p>Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma receiving KEYTRUDA (the approved indication in the United States), including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients, respectively. Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 pneumonitis.&nbsp;<\/p>\n<p>Colitis (including microscopic colitis) occurred in 4 (1%) of 411 patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients respectively, receiving KEYTRUDA. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.&nbsp;<\/p>\n<p>Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411 patients, including a Grade 4 case in 1 (0.2%) patient, receiving KEYTRUDA. Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.&nbsp;<\/p>\n<p>Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2 case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3; and permanently discontinue KEYTRUDA for Grade 4 hypophysitis.&nbsp;<\/p>\n<p>Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of interstitial nephritis with renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients for changes in renal function.&nbsp; Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.<\/p>\n<p>Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients, including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA. Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. Administer corticosteroids for Grade 3 or greater hyperthyroidism. Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with replacement therapy without treatment interruption and without corticosteroids.&nbsp;<\/p>\n<p>Other clinically important immune-mediated adverse reactions can occur. The following clinically significant, immune-mediated adverse reactions occurred in less than 1% of patients treated with KEYTRUDA: exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures arising in a patient with inflammatory foci in brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic neuritis, and rhabdomyolysis.&nbsp;<\/p>\n<p>For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement of the adverse reaction to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or less. Permanently discontinue KEYTRUDA for any severe or Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.&nbsp;<\/p>\n<p>Based on its mechanism of action, KEYTRUDA may cause fetal harm when administered to a pregnant woman. If used during pregnancy, or if the patient becomes pregnant during treatment, apprise the patient of the potential hazard to a fetus. Advise females of reproductive potential to use highly effective contraception during treatment and for 4 months after the last dose of KEYTRUDA.&nbsp;<\/p>\n<p>For the treatment of advanced melanoma, KEYTRUDA was discontinued for adverse reactions in 6% of 89 patients who received the recommended dose of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious adverse reactions occurred in 36% of patients receiving KEYTRUDA. The most frequent serious adverse drug reactions reported in 2% or more of patients were renal failure, dyspnea, pneumonia, and cellulitis.&nbsp;<\/p>\n<p>The most common adverse reactions (reported in \u226520% of patients) were fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%), decreased appetite (26%), constipation (21%), arthralgia (20%), and diarrhea (20%).&nbsp;<\/p>\n<p>The recommended dose of KEYTRUDA is 2 mg\/kg administered as an intravenous infusion over 30 minutes every three weeks until disease progression or unacceptable toxicity. No formal pharmacokinetic drug interaction studies have been conducted with KEYTRUDA. It is not known whether KEYTRUDA is excreted in human milk. Because many drugs are excreted in human milk, instruct women to discontinue nursing during treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not been established in pediatric patients.<b>&nbsp;<\/b><\/p>\n<p>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a> and the Medication Guide for KEYTRUDA at <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a><b>&nbsp;<\/b><\/p>\n<p><b>About Advaxis, Inc.<\/b><b>&nbsp;<\/b><\/p>\n<p>Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary <i>Lm<\/i>-LLO platform technology. The <i>Lm<\/i>-LLO technology, using bioengineered live attenuated <i>Listeria monocytogenes<\/i> bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis\u2019s lead <i>Lm<\/i>-LLO immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1\/2 in head and neck cancer, and Phase 1\/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for a Phase 1\/2 immunotherapy study to evaluate the safety and efficacy of MedImmune\u2019s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis\u2019s ADXS-HPV as a treatment for patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck cancer.&nbsp;<\/p>\n<p>Advaxis\u2019s second <i>Lm<\/i>-LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis entered into a clinical trial collaboration agreement with Merck &amp; Co., Inc. (\u201cMerck\u201d), known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis\u2019s <i>Lm<\/i>-LLO cancer immunotherapy, ADXS-PSA, with Merck\u2019s PD-1 checkpoint inhibitor KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab). The planned clinical trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1\/2 study of patients with previously treated metastatic, castration-resistant prostate cancer.&nbsp;<\/p>\n<p>Advaxis is also developing <i>Lm<\/i>-LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. ADXS-cHER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma.&nbsp;&nbsp; Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma.&nbsp; Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc. for pet therapeutics.<\/p>\n<p>For more information please visit <a href=\"http:\/\/www.advaxis.com\/\">www.advaxis.com<\/a>.&nbsp;<b>&nbsp;<\/b><\/p>\n<p><b>Merck\u2019s Focus on Cancer&nbsp;<\/b><b>&nbsp;<\/b><\/p>\n<p>Our goal is to translate breakthrough science into biomedical innovations to help people with cancer worldwide. For Merck Oncology, helping people fight cancer is our passion, supporting accessibility to our cancer medicines is our commitment, and pursuing research in immuno-oncology is our focus to potentially bring new hope to people with cancer. For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=0c98c6a7d75bd282c1c14efec051050a\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.<\/p>\n<p><b>&nbsp;<\/b><b>About Merck&nbsp;<\/b><b>&nbsp;<\/b><\/p>\n<p>Today\u2019s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=1d8340957aa6da51dcbe71ce586d5b9c\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=d700122c99e3b6febe596e752ad0e737\">Twitter<\/a>, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=34b8e38e1ed92e0d57f8ce042f9d58bd\">Facebook<\/a> and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51017975&amp;newsitemid=20150113005234&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=3a228d44a247ce22813f84eca8219b0d\">YouTube<\/a>.<\/p>\n<p><b>&nbsp;<\/b><b>Advaxis Forward-Looking Statement<\/b><\/p>\n<p>This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis\u2019s ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis\u2019s proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis\u2019s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at <a href=\"http:\/\/www.sec.gov\/\">http:\/\/www.sec.gov<\/a>. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.&nbsp;<\/p>\n<p><b>Merck Forward-Looking Statement <\/b><\/p>\n<p>This news release includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck\u2019s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<\/p>\n<p>Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.<\/p>\n<p>Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\">www.sec.gov<\/a>).&nbsp;<\/p>\n<p align=\"center\">***&nbsp;<\/p>\n<p><b>CONTACTS:&nbsp;<\/b>&nbsp;<\/p>\n<p><b>Company:<\/b><\/p>\n<p><a href=\"http:\/\/www.advaxis.com\/\">Advaxis, Inc.<\/a><\/p>\n<p>Greg Mayes, Executive Vice President and COO<\/p>\n<p><a href=\"mailto:mayes@advaxis.com\">mayes@advaxis.com<\/a><\/p>\n<p>609.452.9813 ext. 102<\/p>\n<p><b>Media Contact:<\/b><\/p>\n<p><a href=\"http:\/\/www.tiberend.com\/\">Tiberend Strategic Advisors, Inc.<\/a><\/p>\n<p>Amy S. Wheeler<\/p>\n<p><a href=\"mailto:awheeler@tiberend.com\">awheeler@tiberend.com<\/a><\/p>\n<p>646.362.5750&nbsp;<\/p>\n<p><b>For Merck (Media):<\/b><\/p>\n<p>Pam Eisele<\/p>\n<p>267.305.3558&nbsp;<\/p>\n<p>Claire Mulhearn<\/p>\n<p>908.236.1118<\/p>\n<p><b>For Merck (Investors):<\/b><\/p>\n<p>Justin Holko<\/p>\n<p>908.740.1879<\/p>\n<p><b>KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, N.J., USA<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1\/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA\u00ae (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis\u2019s lead Lm-LLO immunotherapy candidate for prostate cancer.&nbsp; It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer.&nbsp; ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745228","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1\/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA\u00ae (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis\u2019s lead Lm-LLO immunotherapy candidate for prostate cancer.&nbsp; It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer.&nbsp; ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\\\/\",\"name\":\"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\\\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-04-08T06:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\\\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/","og_locale":"en_US","og_type":"article","og_title":"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer - Merck.com","og_description":"KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1\/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA\u00ae (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis\u2019s lead Lm-LLO immunotherapy candidate for prostate cancer.&nbsp; It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer.&nbsp; ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:17+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/","name":"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-04-08T06:30:00+00:00","dateModified":"2025-11-07T06:25:17+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/advaxis-and-merck-announce-initiation-of-enrollment-in-the-phase-1-2-study-of-adxs-psa-in-combination-with-anti-pd-1-therapy-keytruda-pembrolizumab-for-the-treatment-of-advanced-prostate-can\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1\/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA\u00ae (pembrolizumab), for the Treatment of Advanced Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"88f0e1a3-c42a-4f04-b5f1-41319a8f46ee","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Advaxis-and-Merck-Announce-Initiation-of-Enrollment-in-the-Phase-12-Study-of-ADXS-PSA-in-Combination-with-Anti-PD-1-Therapy-KEYTRUDA--UFKUY.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745228\/revisions"}],"predecessor-version":[{"id":3674661,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745228\/revisions\/3674661"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745228"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}